1. Scl gene construction, expression and effect on hemangioma
- Author
-
Zehua Zhang, Tian-tuo Zhang, B. Zhou, S. S. Yang, X. Fu, Huixiang Yin, Xiao-Ping Yi, Zhenwang Liu, Ailian Zhang, Ce-Yi Fu, Jinxian Luo, and Jincheng Shen
- Subjects
Angiogenesis ,Molecular Sequence Data ,Angiogenesis Inhibitors ,Apoptosis ,Biology ,Pichia ,Hemangioma ,Cell Line, Tumor ,Genetics ,medicine ,Animals ,Humans ,Molecular Biology ,Hyperplasia ,Angiostatin ,Base Sequence ,Neovascularization, Pathologic ,fungi ,Endothelial Cells ,General Medicine ,medicine.disease ,Molecular biology ,Angiogenesis inhibitor ,body regions ,Endothelial stem cell ,medicine.anatomical_structure ,Immunology ,Peptides ,Chickens ,Blood vessel - Abstract
Hemangioma is a tumor that causes vascular endothelial cell hyperplasia, which commonly occur in newborns. Angiogenesis inhibitor targets the processes of angiogenesis, including the proliferation of vascular endothelial cells. A DNA sequence named Scl was designed, recombined into Pichia Pastoris, expressed by fermenting the engineered strain in a bioreactor, and purified the recombinant Scl by SP-sepharose fast flow. Scl can inhibit CAM angiogenesis. Only 1 μg of Scl significantly suppressed the growth of CAM blood vessel, similar to that of 25 μg of angiostatin. Scl showed a strong cytotoxicity on hemangioma cell (ATCC CRL No. 2587). After the drug acted for 24 h, the OD 570 measured value of the PBS control group averaged 1.873, whereas that of the Sc1 drug group was 0.692 (P
- Published
- 2012
- Full Text
- View/download PDF